Test Price
700 AED✅ Home Collection Available
Chromosome 11q Deletion (ATM) FISH Test – 700 AED – DHA Licensed
Executive Summary & Core Metrics
- Diagnostic Accuracy: 99.9% sensitivity and specificity through ISO 9001:2015 certified processing and validated FISH probes for locus-specific detection.
- Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Post-Test Consultation: Telephone follow-up with a consultant medical geneticist to interpret results and guide clinical decision-making.
- Insurance Verification: Direct billing confirmation via WhatsApp at +971545488731 (daily 8 AM – 11 PM).
Test Overview & Methodology
The Chromosome 11q Deletion (ATM) FISH Test detects the loss of the ATM gene locus on chromosome 11q22.3, a well-established adverse prognostic biomarker in chronic lymphocytic leukemia and multiple myeloma. Fluorescence In‑Situ Hybridization (FISH) using locus-specific probes enables high-resolution, quantitative detection of deletions that are invisible to conventional karyotyping. This information directly informs risk stratification, guides targeted therapy selection (e.g., BTK inhibitors or proteasome inhibitors), and supports early multidisciplinary management planning.
| Feature | FISH (DHA Standard) | Conventional Karyotyping |
|---|---|---|
| Analytical Sensitivity | ~98% for 11q22.3 deletion | Low resolution; misses microdeletions |
| Methodology | Fluorescence In‑Situ Hybridization (FISH) | G‑banding metaphase analysis |
| Turnaround Time | 3–4 business days | 7–14 business days |
| Specimen Requirement | Bone marrow aspirate or peripheral blood | Bone marrow aspirate (cultured) |
| Clinical Utility | Direct risk stratification for CLL & MM therapy planning | Broad chromosomal overview only |
Physician Insight & Safety Protocols
“An ATM deletion identified by FISH is a powerful independent adverse prognostic marker in CLL and multiple myeloma. However, this result must always be interpreted within the full clinical context — including IGHV mutation status, serum beta‑2 microglobulin, and LDH levels. I strongly recommend discussing the FISH report with your oncologist or hematologist to integrate it into a personalized treatment strategy that may include targeted therapies or transplant consultation.”
— Ms. Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory: Clinical Considerations Prior to Testing
This test provides prognostic information only and does not replace a complete diagnostic workup or consultation with your treating physician. All therapeutic decisions — including initiation, modification, or discontinuation of medication — must be made by your healthcare provider based on the full clinical picture. Federal Decree-Law No. 4 of 2016 on Medical Liability governs patient consent and procedural safety standards for all sample collection procedures.
Exclusion Criteria and Safety Red Flags
- Hospital-Only Requirement: Bone marrow aspiration must be performed in an accredited hospital setting under sterile conditions. Patients with active bleeding disorders, severe thrombocytopenia (platelets <20,000/µL), or uncontrolled coagulopathy are excluded from outpatient collection.
- Informed Consent: A signed consent form per Federal Decree-Law No. 4 of 2016 is mandatory. For minors, a legal guardian must provide consent and be present during the procedure.
- Emergency Red Flags: Seek immediate medical attention if you experience sudden severe pain, swelling or bleeding at the aspiration site, fever above 38.5 °C, or signs of infection after the procedure.
Patient FAQ & Clinical Guidance
1. What does a positive ATM deletion result mean for my CLL prognosis?
A positive result identifies high-risk CLL and is associated with shorter progression-free survival with standard chemoimmunotherapy. It serves as an independent adverse prognostic factor that often guides the use of targeted therapies such as BTK inhibitors (ibrutinib, acalabrutinib) or BCL‑2 inhibitors (venetoclax). Your oncologist will correlate this finding with IGHV mutation status and other markers for a comprehensive risk profile.
2. How is the sample collected and processed in the UAE?
Sample collection is performed exclusively within a DHA-licensed hospital facility by an accredited hematologist or oncologist. Bone marrow aspirate or peripheral blood is obtained under sterile conditions, immediately stabilized in appropriate transport media, and couriered to our ISO 9001:2015 certified laboratory under temperature-controlled chain of custody. FISH analysis is conducted using FDA-cleared probes with digital imaging and automated signal enumeration, with results delivered within 3–4 business days.
3. What do ATM deletion results indicate for multiple myeloma patients?
In multiple myeloma, ATM deletion is a marker of elevated risk and may influence the choice of proteasome inhibitors (bortezomib, carfilzomib) or the timing of autologous stem cell transplant consultation. It is associated with more aggressive disease behavior and shorter time to progression. Your specialist will integrate this result with serum beta‑2 microglobulin, LDH, and albumin levels to refine your Revised International Staging System (R‑ISS) classification.
4. Is genetic counseling available after the test?
Yes, a post-test telephone consultation with a consultant medical geneticist is included in the service package. This session addresses the implication of the deletion for you and your family, discusses reproductive risks if relevant, and provides referrals to specialist hematologists or oncologists for coordinated care planning.
UAE Regulatory & Data Privacy Adherence
Data Protection and Compliance Framework
All personal health information processed during the Chromosome 11q Deletion (ATM) FISH Test is handled in strict accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. These laws mandate robust consent management, data minimization, encryption during transmission and storage, and the right to access, correct, or delete your data. DNA Labs UAE implements audited information security controls aligned with ISO 27001 principles to safeguard your protected health information.
DHA Facility License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
Clinical & Logistical Metadata
| Test Name | Chromosome 11q Deletion (ATM) FISH Test |
| Price (AED) | 700 |
| Turnaround Time | 3–4 business days |
| Sample Type / Matrix | Bone marrow aspirate or peripheral blood (hospital extraction only) |
| Methodology Used | Fluorescence In‑Situ Hybridization (FISH) – Locus-specific probe for 11q22.3 |
| ICD-10-CM Code | C91.1, C90.0 |
| LOINC Code | 53929-6 |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians